Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.39 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.33 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.32 |
| ▸ | IDH1 | O75874 | 1/20 | 0.32 |
| ▸ | IDH2 | P48735 | 1/20 | 0.32 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.31 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.31 |
| ▸ | TAS2R14 | Q9NYV8 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | OGA | O60502 | 1/20 | 0.31 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3295796 | 0.86 | TRPV4 (0.48) | TRPV4KDM4ECXCR4HSP90AA1HSP90AB1 | |
| SCHEMBL47578 | 0.86 | TSHR (0.38) | KDM4ETSHR | |
| SCHEMBL31613907 | 0.80 | TRPV4 (0.37) | TRPV4KDM4ECXCR4IDH1IDH2 | |
| SCHEMBL12668141 | 0.78 | TSHR (0.33) | KDM4ETSHR | |
| SCHEMBL335132 | 0.77 | HSP90AA1 (0.39) | TRPV4KDM4ECXCR4HSP90AA1HSP90AB1 | |
| SCHEMBL21719322 | 0.77 | — | — | |
| SCHEMBL30612218 | 0.77 | HSP90AA1 (0.39) | TRPV4KDM4ECXCR4HSP90AA1HSP90AB1 | |
| SCHEMBL21794149 | 0.77 | TRPV4 (0.34) | TRPV4 | |
| SCHEMBL30395779 | 0.74 | TRPV4 (0.39) | TRPV4 | |
| SCHEMBL18401507 | 0.74 | TSHR (0.31) | TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11242332-B2 | Method for producing benzimidazole derivative | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2022-02-08 | — | — | US | disclosed |
| US-20200071295-A1 | METHOD FOR PRODUCING BENZIMIDAZOLE DERIVATIVE | Sumitomo Pharma Co., Ltd. (JP) | 2020-03-05 | — | — | US | disclosed |
| US-10407435-B2 | Diheteroaryl histone deacetylase inhibitors and their use in therapy | KARUS THERAPEUTICS LIMITED (GB) | 2019-09-10 | — | — | US | disclosed |
| US-20170313712-A1 | DIHETEROARYL HISTONE DEACETYLASE INHIBITORS AND THEIR USE IN THERAPY | KARUS THERAPEUTICS LIMITED (GB) | 2017-11-02 | — | — | US | disclosed |
| US-20170313712-A1 | DIHETEROARYL HISTONE DEACETYLASE INHIBITORS AND THEIR USE IN THERAPY | KARUS THERAPEUTICS LIMITED (GB) | 2017-11-02 | — | — | US | disclosed |
| US-8987268-B2 | Pyrrolopyridazine JAK3 inhibitors and their use for the treatment of inflammatory and autoimmune diseases | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-03-24 | — | — | US | disclosed |
| US-20140011800-A1 | PYRROLOPYRIDAZINE JAK3 INHIBITORS AND THEIR USE FOR THE TREATMENT OF INFLAMMATORY AND AUTOIMMUNE DISEASES | BRISTOL-MYERS SQUIBB COMPANY | 2014-01-09 | — | — | US | disclosed |
| US-8440672-B2 | Diphenyl substituted alkanes | MERCK SHARP & DOHME CORP. (US) | 2013-05-14 | — | — | US | disclosed |
| US-8426413-B2 | Diaryl substituted alkanes | MERCK SHARP & DOHME CORP. (US) | 2013-04-23 | — | — | US | disclosed |
| US-20120149674-A1 | Diaryl Substituted Alkanes | MERCK SHARPE & DOHME CORP. (US) | 2012-06-14 | — | — | US | disclosed |
| US-8124628-B2 | Diaryl substituted alkanes | MERCK SHARP & DOHME CORP. (US) | 2012-02-28 | — | — | US | disclosed |
| US-20110003815-A1 | DIPHENYL SUBSTITUTED CYCLOALKANES | MERCK & CO., INC. | 2011-01-06 | — | — | US | disclosed |
| US-20100190761-A1 | DIPHENYL SUBSTITUTED ALKANES | MERCK SHARP & DOHME CORP. | 2010-07-29 | — | — | US | disclosed |
| US-20100168076-A1 | DIPHENYL SUBSTITUTED ALKANES | MERCK SHARP & DOHME CORP. | 2010-07-01 | — | — | US | disclosed |
| US-20090258851-A1 | DIARYL SUBSTITUTED ALKANES | MERCK SHARP & DOHME CORP. | 2009-10-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110003815-A1 | DIPHENYL SUBSTITUTED CYCLOALKANES | PTGIS, PTGS1, LTC4S | TRPV4 1030/4885GABRA2 3420/4885GABRB2 2512/4885 |
| US-20170313712-A1 | DIHETEROARYL HISTONE DEACETYLASE INHIBITORS AND THEIR USE IN THERAPY | HDAC1, HDAC11, HDAC7 | TRPV4 4398/4885GABRA2 2926/4885GABRB2 2584/4885 |
| US-20100168076-A1 | DIPHENYL SUBSTITUTED ALKANES | ALOX5, ALOX15, ALOX15B | TRPV4 778/4885GABRA2 3509/4885GABRB2 3400/4885 |
| US-10407435-B2 | Diheteroaryl histone deacetylase inhibitors and their use in therapy | HDAC1, HDAC11, HDAC7 | TRPV4 4398/4885GABRA2 2926/4885GABRB2 2584/4885 |
| US-20140011800-A1 | PYRROLOPYRIDAZINE JAK3 INHIBITORS AND THEIR USE FOR THE TREATMENT OF INFLAMMATORY AND AUTOIMMUNE DISEASES | JAK3, JAK1, JAK2 | TRPV4 2265/4885GABRA2 2129/4885GABRB2 2543/4885 |
| US-11242332-B2 | Method for producing benzimidazole derivative | CYP3A4, CYP3A5, CYP3A43 | TRPV4 2594/4885GABRA2 792/4885GABRB2 817/4885 |
| US-20120149674-A1 | Diaryl Substituted Alkanes | ALOX5, ALOX15, LTB4R2 | TRPV4 1060/4885GABRA2 3185/4885GABRB2 3216/4885 |
| US-20090258851-A1 | DIARYL SUBSTITUTED ALKANES | ALOX5, ALOX15, LTB4R2 | TRPV4 1060/4885GABRA2 3185/4885GABRB2 3216/4885 |
| US-20200071295-A1 | METHOD FOR PRODUCING BENZIMIDAZOLE DERIVATIVE | CYP3A4, CYP3A5, CYP3A43 | TRPV4 2594/4885GABRA2 792/4885GABRB2 817/4885 |
| US-20100190761-A1 | DIPHENYL SUBSTITUTED ALKANES | ALOX5, ALOX15, ALOX15B | TRPV4 1080/4885GABRA2 3495/4885GABRB2 3302/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.